Cyclosporine modified (Neoral)
Class/mechanism: Cyclic polypeptide immunosuppressive agent that reversibly and preferentially inhibits T-lymphocytes, especially the T-helper cell. Exact mechanism unknown. Suppresses humoral immunity and cell-mediated immune reactions, including graft vs. host disease, allograft rejection, delayed hypersensitivity, experimental allergic encephalomyelitis, and Freund’s adjuvant arthritis. The Neoral formulation forms a microemulsion when present in an aqueous environment.
Please choose from the products below to find specific drug/manufacturer information:
- Neoral and Gengraf have higher bioavailability than Cyclosporine non-modified (Sandimmune), and particularly close attention should be given to monitoring of dose levels when changing between Neoral/Gengraf and Sandimmune.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
Also known as
- Generic names: ciclosporin, CsA, CyA, cyclosporin, cyclosporin A
- Brand names: Gengraf, Neoral
- Neoral manufacturer's website
- Cyclosporine modified (Neoral) package insert
- Cyclosporine modified (Neoral) package insert (locally hosted backup)
- Gengraf manufacturer's website
- Cyclosporine modified (Gengraf oral) package insert
- Cyclosporine modified (Gengraf oral) package insert (locally hosted backup)
- Cyclosporine modified (Gengraf capsule) package insert
- Cyclosporine modified (Gengraf capsule) package insert (locally hosted backup)
- Cyclosporine modified (Neoral) patient drug information (UpToDate)